DocStoX is a free AI-powered research platform for Indian equity markets, covering 5,700+ NSE & BSE stocks with prices, fundamentals, 326 financial ratios, shareholding, FII/DII flows, F&O, IPOs, a visual screener and AI stock scoring.

Yes. DocStoX has a free tier covering stock research, the screener, FII/DII data and educational guides, plus a free MCP API tier (50 tool calls/day) for AI assistants. A Pro plan adds higher limits and advanced features.

What data does DocStoX cover?

Every NSE & BSE listed stock (5,700+ instruments): EOD and intraday prices, income statement / balance sheet / cash flow, 326 ratios, quarterly shareholding, promoter pledge, mutual-fund holdings, FII/DII flows, F&O and option-chain data, analyst forecasts, IPOs, corporate actions and news.

Can AI assistants like ChatGPT or Claude use DocStoX data?

Yes. DocStoX runs a public Model Context Protocol (MCP) server at https://mcp.docstox.com/mcp with 76 tools, so Claude, ChatGPT, Cursor and other MCP clients can pull Indian market data directly. Setup and a free key are at https://docstox.com/mcp.

Neutral impactCompany

BASF India Limited — Updates

NSE 1 hr ago·21 Sept 2026, 8:01 am

BASF India

BASF India has informed stock exchanges that it is evaluating a potential investment in its Monomeric Diisocyanate (MDI) business in India. This strategic move signals the company's intent to strengthen its manufacturing footprint and secure a larger share of the domestic chemical market.

For investors, this development is significant as it suggests a long-term commitment to the Indian economy. Expanding local production capacity can enhance BASF India's operational efficiency and competitiveness, which may positively impact its financial performance over time.

Investors should watch for official announcements regarding the final investment decision and the timeline for any expansion projects. These updates will provide clarity on the scale of the opportunity and its potential impact on the company's growth trajectory.